Reaction
Claustrophobia reporting signals
As of the last recalculation, Claustrophobia appears in 1,072 FAERS reports alongside 20 co-occurring drug terms. The strongest observed disproportionality signal is CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES (PRR 20.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 9 | 20.5 | 20.5 |
| Lithium | 22 | 17.3 | 17.3 |
| Lithium Bromatum | 22 | 17.3 | 17.3 |
| Omalizumab | 67 | 16.2 | 16.2 |
| Armodafinil | 15 | 14.0 | 14.0 |
| Lisdexamfetamine Dimesylate | 23 | 13.8 | 13.8 |
| Quetiapine Fumarate | 20 | 13.4 | 13.4 |
| Atomoxetine Hydrochloride | 16 | 13.2 | 13.2 |
| Nicotine Polacrilex Mini | 9 | 11.7 | 11.7 |
| Nicotine Polarilex | 9 | 11.7 | 11.7 |
| Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate | 23 | 11.0 | 11.0 |
| Dolutegravir Sodium | 4 | 8.6 | 8.6 |
| Avapritinib | 5 | 8.0 | 8.1 |
| Cariprazine | 3 | 6.3 | 6.3 |
| Suvorexant | 4 | 6.0 | 6.0 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 5.3 | 5.3 |
| Varenicline Tartrate | 21 | 5.2 | 5.2 |
| Natalizumab | 46 | 5.1 | 5.1 |
| Diroximel Fumarate | 3 | 4.9 | 4.9 |
| Bimekizumab | 4 | 3.7 | 3.7 |